Mongersen Shows Promise for Crohn’s Disease

Mongersen Shows Promise for Crohn’s Disease
shutterstock_139166252A new treatment for Crohn's disease is showing promise in clinical trials. Giuliani, an Italian pharmaceutical company, conducted a phase 2 clinical study of more than 150 adult patients with Crohn's disease and found that a significant number experienced remission of their inflammatory bowel disease after only 28 days of treatment with Mongersen. "There was a pretty high remission rate in a short period of time," commented Dr. Raymond Cross, a gastroenterologist at the University of Maryland Medical Center, who was not involved in the study, in a news release. "That's pretty impressive." Giuliani's new drug, Mongersen, is unique from other biologic treatments for Crohn's disease, such as Remicade and Humira, because it is a pill and the others are injections. According to Dr. Cross, mongersen may also be safer than other medications, but "You can't really assess safety in two weeks," he said. Mongersen, which is under contract to Dublin-based Nogra Pharma, is a SMAD7 antisense oligonucleotide. The drug targets SMAD7 proteins in the ileum and colon to i
Subscribe or to access all post and page content.